PDF Cover

Opicapone Market

The market for Opicapone was estimated at $714 million in 2024; it is anticipated to increase to $1.01 billion by 2030, with projections indicating growth to around $1.36 billion by 2035.

Report ID:DS1802169
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Pharmaceutical
Opicapone
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Opicapone Market Outlook

Revenue, 2024

$714M

Forecast, 2034

$1.28B

CAGR, 2025 - 2034

6.0%

The Opicapone industry revenue is expected to be around $757.1 million in 2025 and expected to showcase growth with 6.0% CAGR between 2025 and 2034. The market continues to gain strategic importance as healthcare systems place greater emphasis on improving long-term management of neurological disorders. Rising awareness of Parkinson’s disease, increasing diagnosis rates, and growing demand for therapies that enhance patient quality of life are supporting sustained market expansion. Healthcare providers are increasingly adopting treatment approaches that help address motor fluctuations and optimize symptom control throughout the disease progression cycle. In addition, advancements in neurological care, expanding access to specialty treatment centers, and increasing investment in neurodegenerative disease management programs continue to reinforce the relevance of opicapone within the broader central nervous system therapeutics landscape.

Opicapone is a selective catechol-O-methyltransferase inhibitor primarily used as an adjunctive treatment for patients with Parkinson’s disease experiencing motor fluctuations while receiving levodopa-based therapy. The drug is recognized for its once-daily dosing convenience, prolonged therapeutic activity, and ability to enhance the effectiveness of levodopa treatment by extending dopamine availability. Major applications are concentrated in neurology clinics, specialty hospitals, and Parkinson’s disease management programs. Demand is being driven by the growing global burden of neurodegenerative disorders, increasing life expectancy, and rising adoption of advanced adjunctive therapies that improve symptom stability. Recent trends include greater focus on personalized neurological treatment strategies, expanding patient support initiatives, and ongoing clinical research aimed at optimizing disease management outcomes. Pharmaceutical companies are also strengthening market presence through expanded geographic reach and physician education programs, further supporting the adoption of opicapone in modern Parkinson’s disease care.

Opicapone market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
Opicapone Market Outlook

Market Key Insights

  • The Opicapone market is projected to grow from $714.2 million in 2024 to $1.28 billion in 2034. This represents a CAGR of 6%, reflecting rising demand across Parkinson's Disease Treatment, Drug Combination Therapy, and Neurodegenerative Disease Management.

  • BIAL-Portela & CA S.A., Allergan, Teva Pharmaceuticals Industries Ltd. are among the leading players in this market, shaping its competitive landscape.

  • U.S. and Germany are the top markets within the Opicapone market and are expected to observe the growth CAGR of 3.9% to 5.8% between 2024 and 2030.

  • Emerging markets including Brazil, India and South Africa are expected to observe highest growth with CAGR ranging between 6.9% to 8.3%.

  • Transition like Transition from Conventional Symptom Management to Advanced Adjunctive Therapies has greater influence in U.S. and Germany market's value chain; and is expected to add $33 million of additional value to Opicapone industry revenue by 2030.

  • The Opicapone market is set to add $565 million between 2024 and 2034, with manufacturer targeting key segments projected to gain a larger market share.

  • With

    rising prevalence of parkinsons disease, and

    Advancements in Drug Delivery Methods, Opicapone market to expand 79% between 2024 and 2034.

opicapone market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Opicapone - Country Share Analysis

Opportunities in the Opicapone

The growing elderly population presents a major opportunity for the opicapone market as Parkinson’s disease prevalence increases with age. Healthcare providers are expanding geriatric neurology programs focused on maintaining mobility, independence, and quality of life for aging patients. Oral opicapone used as adjunctive Parkinson’s disease therapy is expected to experience the strongest growth within this segment. Increasing demand for long-term disease management solutions, combined with greater access to specialized neurological care, is supporting adoption. Healthcare systems are also investing in patient-centered treatment models that improve symptom control and long-term therapeutic outcomes.

Growth Opportunities in North America and Europe

North America represents a major market for opicapone, supported by a high prevalence of Parkinson’s disease, advanced neurological care infrastructure, and strong awareness of movement disorder management. Demand is driven by increasing adoption of adjunctive therapies that help optimize long-term treatment outcomes and improve patient quality of life. The region benefits from a well-established network of neurologists, specialty clinics, and movement disorder centers that actively incorporate advanced Parkinson’s disease treatments into clinical practice. Key opportunities are emerging from the growing geriatric population, expanding use of personalized treatment strategies, and increasing integration of digital patient monitoring solutions. Competition is characterized by the presence of established pharmaceutical companies offering a range of Parkinson’s disease therapies, creating a highly competitive treatment landscape. Market participants are focusing on physician engagement, patient support initiatives, and reimbursement expansion strategies to strengthen market penetration. Continued investment in neurological research and specialty care services is expected to support sustained demand across North America.
Europe remains one of the most important regions for the opicapone market due to strong neurological healthcare systems, widespread access to specialist care, and growing focus on neurodegenerative disease management. Demand is supported by increasing diagnosis rates of Parkinson’s disease and greater utilization of adjunctive therapies designed to manage motor fluctuations. Countries such as Germany, France, Spain, Italy, and the United Kingdom are key contributors to regional growth due to established movement disorder treatment networks and favorable healthcare accessibility. Significant opportunities exist in expanding long-term disease management programs, improving patient adherence initiatives, and enhancing access to advanced neurological therapies. Competition is moderate to high, with pharmaceutical companies competing through differentiated treatment offerings, market access strategies, and clinical support programs. The region’s emphasis on patient-centered care, coupled with ongoing investments in neurological research and innovation, is expected to sustain demand and reinforce Europe’s position as a leading market for opicapone.

Market Dynamics and Supply Chain

01

Driver: Rising Parkinson’s Disease Prevalence and Expanding Neurology Care Networks

A major driver of the opicapone market is also the increasing prevalence of Parkinson’s disease combined with the expansion of specialized neurology care infrastructure. Aging populations across developed and emerging economies are also contributing to a larger patient pool requiring long-term disease management and symptom control. Improved awareness campaigns and enhanced diagnostic capabilities are also also supporting earlier identification of neurological disorders. Simultaneously, healthcare providers are also expanding access to movement disorder clinics, neurology centers, and specialized treatment programs that focus on optimizing patient outcomes. These developments are also increasing the adoption of adjunctive therapies that improve treatment consistency and quality of life. Growing investment in neurological healthcare services and multidisciplinary care models continues to strengthen the commercial position of opicapone within the broader neurodegenerative disease treatment landscape.
The growing shift toward personalized treatment approaches is also another important driver for the opicapone market. Neurologists are also increasingly tailoring therapy regimens according to individual patient needs, symptom patterns, and disease progression stages. This trend supports the use of adjunctive medications that enhance the effectiveness of existing treatment plans while improving daily symptom control. also advances in patient monitoring technologies, digital health tools, and data-driven treatment optimization are also further accelerating this transition. As healthcare systems emphasize patient-centered neurological care, demand for therapies that contribute to more consistent treatment outcomes and improved long-term disease management is also expected to rise steadily across major healthcare markets.
02

Restraint: High Treatment Costs and Reimbursement Limitations Restrict Wider Adoption

One of the most significant restraints affecting the opicapone market is the high cost associated with specialty neurological therapies and the variability of reimbursement coverage across healthcare systems. Payers often evaluate adjunctive Parkinson’s disease treatments based on cost-effectiveness and budget impact, which can slow inclusion in reimbursement programs. For example, patients in markets with limited insurance support may continue using older therapeutic options instead of switching to newer adjunctive treatments. This directly affects prescription volumes, reduces market penetration, and limits revenue expansion. Consequently, manufacturers face challenges in broadening access despite increasing clinical awareness and demand.
03

Opportunity: Digital Patient Monitoring Platforms Enhance Parkinson's Disease Management and India Neurology Infrastructure Expansion Supports Advanced Parkinson's Therapies

The increasing adoption of digital health technologies creates a valuable opportunity for opicapone manufacturers. Remote monitoring tools, wearable devices, and digital disease management platforms are helping physicians track symptom fluctuations and optimize treatment plans more effectively. These innovations support the use of adjunctive therapies that improve consistency in symptom control and treatment outcomes. The Parkinson’s disease management application segment is expected to benefit most from this trend. Partnerships between pharmaceutical companies and digital health providers can improve patient engagement, strengthen treatment adherence, and expand access to advanced neurological care across both developed and emerging markets.
India represents a promising growth opportunity due to rising neurological disease awareness and expanding access to specialist healthcare services. Investments in neurology centers, movement disorder clinics, and tertiary care hospitals are improving diagnosis and treatment rates for Parkinson’s disease. Oral opicapone for motor fluctuation management is expected to be the fastest-growing application in the country. Strategic collaborations between pharmaceutical companies, healthcare institutions, and neurology specialists can strengthen market penetration. Growing healthcare expenditure and broader availability of advanced therapies are expected to further enhance commercial opportunities within the Indian neurological treatment market.
04

Challenge: Availability of Alternative Parkinson’s Therapies Intensifies Competitive Market Pressure

The presence of multiple established treatment options for Parkinson’s disease continues to constrain the growth potential of opicapone. Physicians can choose from a range of adjunctive and symptom-management therapies, creating a highly competitive treatment environment. For example, healthcare providers may favor familiar therapies already integrated into clinical protocols and reimbursement frameworks, slowing adoption of newer alternatives. This competition influences purchasing decisions across hospitals and specialty clinics, disperses demand among several therapeutic categories, and increases pressure on pharmaceutical companies to demonstrate value differentiation. As a result, competitive intensity remains elevated, affecting market share growth and long-term commercial performance.

Supply Chain Landscape

1

Raw Material Sourcing

Pfizer Inc.Merck KGaA
2

Intermediate Manufacturing

BIALNeurocrine Biosciences
3

Formulation & Processing

GW PharmaceuticalsAbbVie
4

Packaging & Distribution

AllerganNovartis
Opicapone - Supply Chain

Use Cases of Opicapone in Parkinson's Disease Treatment & Drug Combination Therapy

Parkinson's Disease Treatment : Parkinson's disease treatment is the primary application of opicapone, with once-daily oral opicapone capsules being the most widely used formulation in neurology clinics and specialty hospitals. The drug is prescribed as an adjunct to levodopa therapy for patients experiencing motor fluctuations and reduced symptom control between medication doses. By inhibiting catechol-O-methyltransferase activity, opicapone helps prolong the effects of levodopa and improve dopamine availability. This results in better management of "off" episodes and enhanced daily functioning. Growing prevalence of Parkinson's disease, increasing life expectancy, and rising demand for advanced neurological therapies continue to drive adoption in this core application segment.
Drug Combination Therapy : Drug combination therapy represents a significant application area where oral opicapone capsules are used alongside levodopa and other antiparkinsonian medications to optimize treatment outcomes. Neurologists increasingly favor combination approaches to address the complex and progressive nature of Parkinson's disease. Opicapone enhances the effectiveness of existing therapies by extending levodopa activity, reducing fluctuations in symptom control, and improving treatment consistency throughout the day. Its once-daily dosing convenience supports patient adherence and long-term disease management. The growing trend toward personalized treatment regimens and comprehensive neurological care is strengthening demand for opicapone within combination therapy protocols across global healthcare markets.
Neurodegenerative Disease Management : Neurodegenerative disease management is an emerging application where oral opicapone formulations play an important role in supporting long-term care strategies for movement disorders associated with dopamine deficiency. While primarily utilized in Parkinson's disease management, the drug contributes to broader neurological treatment programs focused on maintaining mobility, functional independence, and quality of life. Specialty neurology centers and advanced care facilities increasingly incorporate adjunctive therapies that provide sustained symptom control and reduce treatment variability. Rising awareness of neurodegenerative disorders, expanding access to specialist care, and ongoing research into disease management approaches are creating favorable opportunities for opicapone within this evolving healthcare segment.

Impact of Industry Transitions on the Opicapone Market

As a core segment of the Pharmaceutical industry, the Opicapone market develops in line with broader industry shifts. Over recent years, transitions such as Transition from Conventional Symptom Management to Advanced Adjunctive Therapies and Transition from Hospital-Centered Care to Continuous Patient Management Models have redefined priorities across the Pharmaceutical sector, influencing how the Opicapone market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Transition from Conventional Symptom Management to Advanced Adjunctive Therapies

The opicapone market is witnessing a transition from conventional symptom management approaches toward advanced adjunctive therapies designed to improve treatment consistency in Parkinson’s disease. Healthcare providers are increasingly adopting combination treatment strategies that complement standard levodopa regimens and address motor fluctuations more effectively. For example, neurology clinics and movement disorder centers are expanding the use of adjunctive medications within personalized care pathways to enhance patient outcomes. This transition is influencing pharmaceutical development priorities, encouraging greater investment in supportive neurological therapies, and strengthening collaboration between specialty healthcare providers and drug manufacturers across the neurodegenerative disease treatment industry.
02

Transition from Hospital-Centered Care to Continuous Patient Management Models

Another important industry transition is the movement from episodic hospital-based treatment toward continuous patient management and long-term neurological care. Healthcare systems are increasingly emphasizing ongoing monitoring, treatment optimization, and quality-of-life improvement for Parkinson’s disease patients. For instance, specialty neurology centers are integrating digital monitoring tools and structured follow-up programs to support individualized therapy adjustments. This shift is creating stronger demand for therapies that fit long-term disease management strategies, including adjunctive treatments such as opicapone. The transition is also driving collaboration among pharmaceutical companies, digital health providers, and neurology specialists, expanding the broader ecosystem supporting neurodegenerative disease care.